CARMAT Inactive Instrument
Carmat Share Price Other OTC
Equities
Medical Equipment, Supplies & Distribution
| Sales 2024 * | 14.85M 16.16M 1.35B | Sales 2025 * | 37.48M 40.78M 3.4B | Capitalization | 111M 121M 10.1B |
|---|---|---|---|---|---|
| Net income 2024 * | -39M -42.44M -3.54B | Net income 2025 * | -30M -32.65M -2.72B | EV / Sales 2024 * | 11.2 x |
| Net Debt 2024 * | 54.4M 59.2M 4.94B | Net Debt 2025 * | 100M 109M 9.09B | EV / Sales 2025 * | 5.64 x |
| P/E ratio 2024 * |
-2.42
x | P/E ratio 2025 * |
-3.56
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Carmat
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | 53 | 01/16/01 |
| Director of Finance/CFO | - | 12/18/12 | |
Marc Grimmé
CTO | Chief Tech/Sci/R&D Officer | - | 25/08/25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22/22/22 |
Pierre Bastid
BRD | Director/Board Member | 69 | 05/18/05 |
| Director/Board Member | 61 | 07/21/07 |
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
| 1st Jan change | Capi. | |
|---|---|---|
| -4.81% | 11.09B | |
| -1.95% | 8.56B | |
| +40.43% | 5.62B | |
| -27.04% | 4.41B | |
| +7.47% | 3.41B | |
| -15.26% | 2.6B | |
| -12.01% | 2.07B | |
| -13.56% | 1.92B | |
| -29.81% | 1.63B |
